Effects of sitagliptin on coronary atherosclerosis evaluated using integrated backscatter intravascular ultrasound in patients with type 2 diabetes: rationale and design of the TRUST study
Abstract Patients with diabetes mellitus are at high risk for developing coronary artery disease (CAD), even if they are treated with statins. Several studies have shown the beneficial effects of dipeptidyl peptidase-4 (DPP-4) inhibitors on the cardiovascular system in an animal model. However, recent clinical trials using DPP-4 inhibitors have shown that these inhibitors fail to reduce the occurrence of cardiovascular events. Therefore, this study will be performed to evaluate the effects of sitagliptin, a DPP-4 inhibitor, on coronary atherosclerosis in patients with type 2 diabetes. This study will be a prospective, open-label, randomized multicenter trial performed in 6 centers in Japan. Stable CAD patients with type 2 diabetes who have undergone successful percutaneous coronary intervention under integrated backscatter (IB)-intravascular ultrasound (IVUS) guidance will be studied. They will be randomly assigned to either the sitagliptin group or a control group. After 48 weeks’ treatment, the IVUS examination will be repeated in the same coronary artery as at baseline. The primary end point will be the percentage change in plaque volume measured using grayscale IVUS from baseline to the 48-week follow-up. This study will be the first multicenter trial to evaluate the effects of a DPP-4 inhibitor on coronary atherosclerosis evaluated using IB-IVUS, and the findings will clarify the anti-atherogenic effects of sitagliptin..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:31 |
|---|---|
| Enthalten in: |
Heart and vessels - 31(2015), 5 vom: 21. März, Seite 649-654 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Nozue, Tsuyoshi [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: | |
|---|---|
| Themen: |
Coronary atherosclerosis |
| doi: |
10.1007/s00380-015-0662-4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR004561287 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR004561287 | ||
| 003 | DE-627 | ||
| 005 | 20230519170411.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201001s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00380-015-0662-4 |2 doi | |
| 035 | |a (DE-627)SPR004561287 | ||
| 035 | |a (SPR)s00380-015-0662-4-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 082 | 0 | 4 | |a 610 |q ASE |
| 084 | |a 44.85 |2 bkl | ||
| 100 | 1 | |a Nozue, Tsuyoshi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effects of sitagliptin on coronary atherosclerosis evaluated using integrated backscatter intravascular ultrasound in patients with type 2 diabetes: rationale and design of the TRUST study |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Patients with diabetes mellitus are at high risk for developing coronary artery disease (CAD), even if they are treated with statins. Several studies have shown the beneficial effects of dipeptidyl peptidase-4 (DPP-4) inhibitors on the cardiovascular system in an animal model. However, recent clinical trials using DPP-4 inhibitors have shown that these inhibitors fail to reduce the occurrence of cardiovascular events. Therefore, this study will be performed to evaluate the effects of sitagliptin, a DPP-4 inhibitor, on coronary atherosclerosis in patients with type 2 diabetes. This study will be a prospective, open-label, randomized multicenter trial performed in 6 centers in Japan. Stable CAD patients with type 2 diabetes who have undergone successful percutaneous coronary intervention under integrated backscatter (IB)-intravascular ultrasound (IVUS) guidance will be studied. They will be randomly assigned to either the sitagliptin group or a control group. After 48 weeks’ treatment, the IVUS examination will be repeated in the same coronary artery as at baseline. The primary end point will be the percentage change in plaque volume measured using grayscale IVUS from baseline to the 48-week follow-up. This study will be the first multicenter trial to evaluate the effects of a DPP-4 inhibitor on coronary atherosclerosis evaluated using IB-IVUS, and the findings will clarify the anti-atherogenic effects of sitagliptin. | ||
| 650 | 4 | |a Coronary atherosclerosis |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Diabetes mellitus |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Dipeptidyl peptidase-4 inhibitor |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Intravascular ultrasound |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Sitagliptin |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Fukui, Kazuki |e verfasserin |4 aut | |
| 700 | 1 | |a Koyama, Yutaka |e verfasserin |4 aut | |
| 700 | 1 | |a Fujii, Hiroyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Kunishima, Tomoyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Hikita, Hiroyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Hibi, Kiyoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Miyazawa, Akiyoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Michishita, Ichiro |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Heart and vessels |d Tokyo : Springer, 1985 |g 31(2015), 5 vom: 21. März, Seite 649-654 |w (DE-627)SPR004550536 |w (DE-600)1481441-9 |x 1615-2573 |7 nnns |
| 773 | 1 | 8 | |g volume:31 |g year:2015 |g number:5 |g day:21 |g month:03 |g pages:649-654 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s00380-015-0662-4 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.85 |q ASE |
| 951 | |a AR | ||
| 952 | |d 31 |j 2015 |e 5 |b 21 |c 03 |h 649-654 | ||